Economy
Top News
Alteogen Signs Subcutaneous Injection Development Deal With Novartis Worth Up to...
Alteogen has signed an option and licensing agreement with Novartis to develop and commercialize subcutaneous formulations based on its ALT-B4 technology, with potential payments of up to $3.22 billion plus royalties.
- Our Sponsors Ad -